BRIEF-Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoints Of Overall Survival And Progression-Free Survival In Certain Patients With Advanced Or Recurrent Endometrial Cancer

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

May 18 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK ANNOUNCES TROFUSE-005 TRIAL EVALUATING SACITUZUMAB TIRUMOTECAN (SAC-TMT) MET PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) IN CERTAIN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER

  • MERCK CO INC: SAFETY PROFILE WAS CONSISTENT WITH WHAT HAS BEEN OBSERVED IN PREVIOUSLY REPORTED STUDIES OF SAC-TMT

  • MERCK: SAC-TMT SHOWED STATISTICALLY SIGNIFICANT CLINICALLY MEANINGFUL IMPROVEMENT IN OS AND PFS COMPARED TO TREATMENT OF PHYSICIAN'S CHOICE

  • MERCK CO INC: STUDY ALSO REACHED ITS KEY SECONDARY ENDPOINT OF OBJECTIVE RESPONSE RATE

Source text: ID:nBw1w2mVWa

Further company coverage: MRK.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.